Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

Subjects:

Robustness test results. by Yanling Li (269030)

Subjects:

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

Subjects:

Heterogeneity test at different educational levels. by Yanling Li (269030)

Subjects:

Results of baseline regression. by Yanling Li (269030)

Subjects:

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

Subjects:

Comparison of SpO₂ (A), HR (B), SBP (C), and DP (D) on VT among the three oxygen conditions. by Kazufumi Hisamoto (21416905)

Subjects:

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

Subjects:

Unmatched kernel density function diagram. by Yanling Li (269030)

Subjects:

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. by Hammad Ismail (4227988)

Dataset (Figs 2–5). by Xianyong Wang (22601067)

“…Results indicated that high fertilizer treatments significantly increased short-term soil N, P, and K availability; however, their concentrations decreased by day 10 post-application, indicating the necessity for topdressing at 10-day intervals to maintain nutrient effectiveness. …”

Schematic diagram of soil sample collection. by Xianyong Wang (22601067)

“…Results indicated that high fertilizer treatments significantly increased short-term soil N, P, and K availability; however, their concentrations decreased by day 10 post-application, indicating the necessity for topdressing at 10-day intervals to maintain nutrient effectiveness. …”

Changes in the neutrophil count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the platelet count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the white blood cell count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the hemoglobin. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

General clinical data of 88 patients with NPC. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

CONSORT participant flow diagram. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

S4 File - by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”